CCM
ALPN

CAAS Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

CAAS Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,354
Closed -$327K – 1007
2022
Q3 		$327K Buy
+45,354
New +$374K 0.02% 577
2021
Q1 		– Sell
-148,200
Closed -$1.87M – 1447
2020
Q4 		$1.87M Buy
+148,200
New +$1.45M 0.02% 505

Other funds holding ALPN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

CAAS Capital Management's ALPN Position: Q4 2022 in Review

CAAS Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2022, closing a stake of 45,354 shares — an estimated $327K sold.

CAAS Capital Management first reported a position in ALPN in Q4 2020 and held it in 2 quarters. The position peaked at $1.87M in Q4 2020. 63 funds tracked by Wall St. Rank hold ALPN as of Q4 2022.

  • CAAS Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 45,354 Alpine Immune Sciences Inc shares in Q4 2022, an estimated $327K.
  • CAAS Capital Management first reported a position in Alpine Immune Sciences Inc in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's Alpine Immune Sciences Inc position peaked at $1.87M in Q4 2020.
  • 63 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.